Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 1.93 USD -5.85%
Market Cap: 85.4m USD
Have any thoughts about
Adagene Inc?
Write Note

Adagene Inc
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adagene Inc
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Adagene Inc
NASDAQ:ADAG
Other Operating Expenses
$3.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Operating Expenses
ÂĄ210.1m
CAGR 3-Years
12%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Operating Expenses
-ÂĄ208m
CAGR 3-Years
39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Operating Expenses
ÂĄ45.2m
CAGR 3-Years
-7%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Operating Expenses
-ÂĄ184.4m
CAGR 3-Years
N/A
CAGR 5-Years
-31%
CAGR 10-Years
-15%
Imeik Technology Development Co Ltd
SZSE:300896
Other Operating Expenses
ÂĄ25.6m
CAGR 3-Years
147%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Adagene Inc
Glance View

Market Cap
85.4m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.96 USD
Overvaluation 50%
Intrinsic Value
Price

See Also

What is Adagene Inc's Other Operating Expenses?
Other Operating Expenses
3.5m USD

Based on the financial report for Dec 31, 2023, Adagene Inc's Other Operating Expenses amounts to 3.5m USD.

Back to Top